Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ditching Beta-Blockers improve heart function?

NCT ID NCT05174351

Knowledge-focused Sponsor: UConn Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at what happens when people with a certain type of heart failure (HFpEF) stop taking beta-blockers for 4 weeks. Researchers will measure changes in heart function, exercise ability, and quality of life in 30 participants. The goal is to see if stopping this common medication might actually be beneficial for these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta blocker discontinuation
What this could lead to
If successful, this could suggest that some HFpEF patients may do better without beta-blockers, pointing toward a change in treatment guidelines.
What could go wrong
This is a very small pilot study with only 30 participants and no control group. Results may not apply to all HFpEF patients, and stopping beta-blockers could worsen symptoms in some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2021

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stable HFpEF patients with NYHA Class II-III or elevated BNP ≥100 * N=30 (Target: 30). * Age: 50 \~ 80 years. * ECHO evidence of EF ≥50% and Grade 2 or 3 diastolic dysfunction. * Chronic loop diuretic use * Currently on beta-blocker Exclusion Criteria: * Beta blocker was prescribed for treating other cardiac conditions such as atrial fibrillation or coronary artery disease. * Heart rate \> 100 bpm * Recent hospitalization due to HF within 3 months * Non-English speaker

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure with preserved ejection fraction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure with preserved ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UConn Health / John Dempsey Hospital

    RECRUITING

    Farmington, Connecticut, 06030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.